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Abstract  Alzheimer’s  disease  (AD)  is  a  neurodegenerative  dementia  characterized  by  the
deposition  of  extracellular  -amyloid  (A)  plaques  and  the  presence  of  neuroﬁbrillary  tangles.
Until now,  the  techniques  used  to  analyze  these  deposits  have  been  difﬁcult  to  access,  inva-
sive, and  expensive.  This  leads  us  to  consider  new  access  routes  to  the  central  nervous  system
(CNS), allowing  us  to  diagnose  the  disease  before  the  ﬁrst  symptoms  appear.  Recent  studies
have shown  that  microglial  and  macroglial  cell  activation  could  play  a  role  in  the  development
of this  disease.  Glial  cells  in  the  CNS  can  respond  to  various  damages,  such  as  neurodegener-
ative pathologies,  with  morphological  and  functional  changes.  These  changes  are  a  common
feature in  neurodegenerative  diseases,  including  AD.  The  retina  is  considered  an  extension  of
the CNS  and  has  a  population  of  glial  cells  similar  to  that  of  the  CNS.  When  glial  cells  are  acti-
vated, various  molecules  are  released  and  changes  in  glial  cell  expression  occur,  which  can  be
indicators  of  neuronal  damage.  The  objective  of  this  review  is  to  compile  the  most  relevant
ﬁndings in  the  last  10  years  relating  to  alterations  in  the  eye  in  AD,  and  the  role  that  glial  cells
play in  the  degenerative  process  in  the  retina  in  the  context  of  neurodegeneration.
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Resumen  La  enfermedad  de  Alzheimer  (EA)  es  una  demencia  neurodegenerativa  que  se  carac-
teriza por  la  deposición  de  placas  beta-amiloides  (A)  extracelulares,  y  la  presencia  de  ovillos
neuroﬁbrilares.  Hasta  ahora,  las  técnicas  utilizadas  para  analizar  estos  depósitos  han  sido  poco
accesibles,  invasivas  y  costosas.  Esto  nos  lleva  a  considerar  nuevas  vías  de  acceso  al  sistema
nervioso central  (SNC)  que  nos  permitan  diagnosticar  la  enfermedad  antes  de  la  aparición  de
sus primeros  síntomas.  Los  estudios  recientes  han  reﬂejado  que  la  activación  de  las  células
microgliales  y  macrogliales  podría  desempen˜ar  un  papel  en  el  desarrollo  de  esta  enfermedad.
Las células  gliales  del  SNC  pueden  responder  a  diversos  dan˜os,  tales  como  patologías  neurode-
generativas,  con  cambios  morfológicos  y  funcionales.  Dichos  cambios  son  una  característica
común en  las  enfermedades  neurodegenerativas,  incluyendo  la  EA.  La  retina  se  considera  una
extensión  del  SNC,  y  cuenta  con  una  población  de  células  gliales  similar  a  la  de  dicho  sistema.
Cuando las  células  gliales  se  activan,  se  liberan  diversas  moléculas,  y  se  producen  diversos
cambios en  la  expresión  de  las  células  gliales,  que  pueden  ser  indicadores  de  dan˜o  neuronal.
El objetivo  de  esta  revisión  es  recopilar  los  hallazgos  más  relevantes  de  los  últimos  diez  an˜os,
con relación  a  las  alteraciones  oculares  en  la  EA,  y  el  papel  que  juegan  las  células  gliales  en  el
proceso degenerativo  de  la  retina  en  el  contexto  de  la  neurodegeneración.
© 2018  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  licencia  CC  BY-NC-ND  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).
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lzheimer’s  disease  (AD)  is  a  disabling  and  progressive  neu-
odegenerative  disease  with  no  cure  that  leads  to  cognitive
mpairment  and  memory  loss,  affecting  millions  of  people
round  the  world.1 Because  the  retina  is  considered  an
xtension  of  the  central  nervous  system  (CNS),  it  seems  clear
hat  the  use  of  new,  non-invasive  retinal  analysis  techniques
ould  allow  for  the  evaluation  of  retinal  glial  cell  activation,
nd  establish  this  as  a  new  tool  for  AD  diagnosis.  This  review
ives  a  brief  description  of  AD  and  its  manifestations  in  the
ye,  as  well  as  a  description  of  glial  cells  and  their  changes
n  this  disease.
aterial and methods
 literature  search  was  performed  up  to  September
017  using  the  MEDLINE  database,  PubMed,  and  Google
cholar  search  services  with  the  following  key  words  and
ord  combinations:  Alzheimer,  glia,  glia-retina,  Alzheimer-
lia,  Alzheimer-astrocytes,  Alzheimer-microglia,  Alzheimer-
ye,  Alzheimer-retina,  Alzheimer-glia-eye,  Alzheimer-glia-
etina,  and  Alzheimer-Müller  cells.  After  ﬁltering  by  author
riteria  (articles  published  in  the  last  10  years),  English  or
panish  language,  and  the  condition  that  all  address  the
elationship  between  AD  and  retinal  glial  cells  as  the  main
ubject,  250  articles  were  considered.
lzheimer’s diseasePlease  cite  this  article  in  press  as:  Fernández-Albarral  JA,  et  a
J  Optom.  (2018),  https://doi.org/10.1016/j.optom.2018.07.00
D  is  a  progressive  neurodegenerative  disease  characterized
y  a  decline  in  cognitive  function  and  memory  resul-
ing  from  synapse  and  cell  loss,  accompanied  by  a  strong
u
t
c
deuroinﬂammatory  response.  It  accounts  for  60--80%  of
ementia  cases,  and  is  the  leading  cause  of  these  in  the
opulation  over  60  years  old.2
AD  may  be  familial  or  sporadic  in  origin.  The  incidence
f  familial  cases  is  low  (5--10%),  and  is  related  to  mutations
n  three  different  genes:  amyloid  precursor  protein  (APP),
resenilin  1  (PSEN-1)  and  presenilin  2  (PSEN-2).  Sporadic
D  accounts  for  90--95%  of  all  cases,  and  has  a  multifac-
orial  pathogenesis  consisting  of  a  combination  of  genetic
nd  environmental  factors,  in  which  age  is  the  leading  risk
actor.3 The  main  gene  associated  with  the  sporadic  mani-
estation  of  the  disease  is  the  apolipoprotein  E  gene  (APOE).
f  the  three  isoforms,  APOE  4  is  found  in  50%  of  patients
ffected  by  AD  and  carries  a  three-fold  risk  of  developing
he  disease.  In  the  CNS,  APOE  is  expressed  predominantly
y  astrocytes  but  also  by  microglia.4,5
Pathologically,  AD  is  characterized  by  deposits  of  extra-
ellular  plaques  of  -amyloid  (A)  peptide  or  senile  plaques
nd  neuroﬁbrillary  tangles  (NFTs)  resulting  from  intra-
ellular  aggregates  of  hyperphosphorylated  tau  protein.6
eposition  of  A  plaques,  the  ﬁrst  manifestation  of  the
athogenesis  of  AD,  begins  many  years  before  symptoms
ppear.  Although  tau  protein  aggregation  occurs  after  the
ppearance  of  the  senile  plaques,  it  is  evident  before  the
linical  onset  of  the  disease.  These  characteristic  changes
re  well-reﬂected  in  the  cerebrospinal  ﬂuid  (CSF),  which
emonstrates  altered  levels  of  tau  protein  and  phosphory-
ated  tau,  as  well  as  A  levels  at  the  onset  of  the  disease
athogenesis.  The  changes  in  these  biomarkers  can  be  seen
ven  in  the  preclinical  stages  of  the  disease,  and  can  be
seful  to  determine  which  patients  will  develop  AD  overl.  Retinal  glial  changes  in  Alzheimer’s  disease  --  A  review.
1
ime.7 A  clinical  diagnosis  of  AD  can  only  be  deﬁnitively
onﬁrmed  by  a  post-mortem  examination  of  the  brain.  A
iagnosis  of  probable  AD  is  possible  only  when  the  disease
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has  considerably  progressed,  and  neurological  damage  has
already  occurred.8
Glial cells
Glia  are  a  highly  homogeneous  population  of  non-excitable
cells  distributed  throughout  the  CNS,  and  are  essential
for  normal  brain  function.9 The  main  function  of  the  glia
is  to  maintain  the  homeostasis  of  the  nervous  tissue  and
to  control,  protect,  and  support  neuronal  function.  They
also  respond  to  CNS  injuries  as  a  defense  mechanism,  and
when  dysfunctional,  they  can  even  be  primary  pathogenic
agents.10 In  the  CNS,  astrocytes  and  oligodendrocytes  are
neuroectodermic  in  origin,  and  make  up  the  macroglia.
Microglia  originate  from  the  mesoderm,  and  are  considered
the  macrophagous  element  of  the  CNS.9
Astrocytes
The  main  population  of  glial  cells  consists  of  astrocytes.
They  account  for  about  one  in  three  cells  of  the  brain  mass.
They  are  essential  for  correct  homeostasis  in  the  brain  tis-
sue  and  for  neuronal  function,  and  create  a  barrier  around
blood  vessels  that  limits  the  passage  of  immune  cells  to  the
CNS.  Astrocytes  are  resistant  to  cell  death  by  apoptosis,
and  are  therefore  able  to  survive  attacks  from  inﬂammatory
processes.
The  main  functions  of  astrocytes  include  metabolic  sup-
port  of  the  neurons  and  their  dendrites  and  synapses,
glycogen  storage  and  lactate  export,  neurotransmitter
uptake,  including  glutamate,  protection  against  reactive
oxygen  species  (ROS),  provision  of  neurotrophic  factors  to
neurons  and  oligodendrocytes  following  injury  such  as  nerve
growth  factor  (NGF),  ciliary  neurotrophic  factor  (CNTF)  and
tumor  necrosis  factor  (TNF-) among  others,  homeosta-
sis,  blood-brain  barrier  (BBB)  induction  and  maintenance,
scar  formation  and  tissue  repair,  and  regulation  of  immune
response  in  the  CNS.11
The  astrocyte  processes  stending  radially  out  from  the
cell  body  give  it  a  stellate  appearance.  The  cytoplasm  of
these  cells  contains  a  large  number  of  intermediate  ﬁla-
ments  composed  of  glial  ﬁbrillary  acidic  protein  (GFAP),
which  is  speciﬁc  to  astrocytes  and  reactive  Müller  cells  and
allows  them  to  be  selectively  labeled  via  immunocytochem-
ical  techniques.12
Astroglia  play  a  central  role  in  responding  to  all  forms
of  pathological  conditions  such  as  trauma,  ischemia,  and
neurodegenerative  diseases.  It  has  been  suggested  that
reactive  astroglia  (astrogliosis)  either  release  neurotrophic
factors  to  support  cell  survival  or  produce  molecules  that
inhibit  axonal  repair  and  regeneration,  triggering  neurolog-
ical  cytotoxicity,  which  causes  secondary  damage  in  nearby
neurons.13 A  better  understanding  of  glial  reactions  to
lesions  and  their  contribution  to  the  development  of  the
disease  can  assist  in  designing  new  treatment  strategies.14Please  cite  this  article  in  press  as:  Fernández-Albarral  JA,  et  a
J  Optom.  (2018),  https://doi.org/10.1016/j.optom.2018.07.00
Oligodendrocytes
Oligodendrocytes  make  up  about  5--10%  of  the  total  glial  cell
population.  They  are  essential  for  the  rapid  and  efﬁcient
I
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onduction  of  electrical  impulses  along  the  axons,  as  well
s  for  preserving  axonal  integrity.15 Oligodendrocytes  have
 very  limited  capacity  for  regeneration;  the  injury  of  just  a
ew  can  create  an  appreciable  area  of  demyelination.  They
re  the  ﬁrst  nervous  elements  that  degenerate  in  diseases
f  the  CNS  where  myelin  is  affected.16 In  the  retinas  of  most
ertebrates,  the  axons  are  unmyelinated.  Oligodendrocytes,
hich  are  responsible  for  axonal  myelination  in  the  CNS,  are
herefore  absent  in  the  retina.17
icroglia
icroglia  are  the  cells  that  make  up  the  CNS  immune  sys-
em,  and  are  found  in  all  regions  of  the  CNS,  including
he  retina.18 They  represent  5--10%  of  all  adult  human
rain  cells.4 Their  functions  include  surveillance  of  the  sur-
ounding  environment,  elimination  of  invading  microbes,
learance  of  cellular  debris,  and  enforcement  of  pro-
rammed  cell  death  via  the  removal  of  apoptotic  cells.
hey  also  release  brain  derived  neurotrophic  factor  (BDNF)
nd  anti-inﬂammatory  cytokines  involved  in  neuronal  sur-
ival.  Therefore,  in  addition  to  their  role  as  immune  defense
ells,  they  are  vital  for  the  endogenous  repair  of  nerve
athways.  Along  with  their  anti-inﬂammatory  and  neuro-
rotective  effects,  they  play  a  critical  role  in  the  normal
evelopment  of  angiogenesis.
Microglia  are  a  dynamic  cellular  population  and  exist  in
arious  states  of  activation  associated  with  distinct  mor-
hological  transformations.19 In  the  absence  of  damage  or
athologies,  they  present  in  their  baseline  or  resting  state.20
ach  of  these  cells  occupies  one  area  and  has  no  physical
ontact  with  the  others.21 Even  in  the  baseline  state,  they
ontinuously  monitor  their  surrounding  environment.
Synaptic  formation  is  regulated  by  the  microglia,  and
eems  to  depend  on  the  production  and  release  of  molecu-
ar  mediators  such  as  BDNF  or  interleukin-10  (IL-10),  among
thers.22 The  ability  of  microglia  to  enhance  the  release
f  BDNF  in  the  context  of  aggression  accelerates  healing
nd  constitutes  a  damage  reduction  mechanism.  It  seems
hat  cytokines  considered  classically  injurious,  such  as  IL-1
nd  TNF-, facilitate  the  phagocytosis  of  cellular  debris  and
rigger  many  other  events  necessary  for  neural  repair.19
Since  adenosine  is  an  important  neuromodulator  of  the
mmune-inﬂammatory  system,  microglia  express  all  sub-
ypes  of  adenosine  receptors  A1, A2A,  A2B and  A3. In  the  case
f  A2AR,  this  protects  neurons  from  primal  proinﬂammatory
eurodegeneration,  however  other  brain  injuries  that  trig-
er  neuroinﬂammation  cause  upregulation  of  this  chemical
n  the  microglial  cells,  where  it  appears  to  play  an  important
ole  in  the  pathophysiology  of  degeneration.22
Microglia  express  both  class  I  and  class  II  major  histo-
ompatibility  complex  molecules  (MHC).  In  the  presence  of
ertain  cytokines  these  increase,  allowing  the  microglia  to
ct  as  antigen-presenting  cells  and  to  become  an  integral
art  of  the  immune  network.19
lial responsel.  Retinal  glial  changes  in  Alzheimer’s  disease  --  A  review.
1
n  situations  such  as  neural  damage,  disease,  or  even
ging,  the  glia  can  respond  by  undergoing  morphological
nd  functional  changes  accompanied  by  the  production  of
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microglial  activation  are  beneﬁcial  in  pathologies  such  asARTICLEPTOM-276; No. of Pages 10
 
roinﬂammatory  cytokines.23 This  general  glial  response
o  aggression  or  inﬂammation  in  the  adult  brain  is  called
eactive  gliosis.24 Reactive  gliosis  has  a  neuroprotective
ffect,  however  chronic  gliosis  exacerbates  disease  progres-
ion  by  increasing  vascular  permeability,  inﬁltration  of  toxic
ompounds,  and  even  through  neovascularization.25 Oligo-
endrocytes  do  not  usually  demonstrate  reactive  changes;
strocytes  and  microglia  are  the  main  populations  of  reac-
ive  glia.23
Microglia  exist  in  a  symbiotic  relationship  with  neurons,
here  microglia  sustain  the  neurons  and  neurons  maintain
he  microglia  in  a  noninﬂammatory  phenotype.19 Because
f  their  ability  to  activate  rapidly  upon  aggression,24 the
icroglia  normally  initiate  and  direct  the  coordinated  neu-
oinﬂammatory  response.
Activated  microglia  change  from  a  ramiﬁed  form  to
 non-phagocytic  hyper-ramiﬁed  or  hypertrophic  pheno-
ype,  and  ﬁnally  to  an  amoeboid  morphology  (especially
f  there  is  degeneration  of  terminals  and/or  neurons),
etracting  their  extensions.  This  allows  migration  through
he  parenchyma  to  the  site  of  the  injury.21 There  are
wo  activated  polarization  states.19 Under  stress  condi-
ions,  microglia  release  anti-inﬂammatory  cytokines  and
rowth  factors,  transition  to  the  M2  phenotype  induced  by
L-4  and  IL-13  and  express  mannose  receptor  CD206  and
rginase  1,  which  downregulate  inﬂammation  and  promote
issue  remodeling/repair  and  angiogenesis.4 When  overacti-
ated,  they  transition  to  the  M1  phenotype,  characterized
y  the  production  of  nitric  oxide  (NO),  superoxide  radi-
als,  proinﬂammatory  cytokines  such  as  IL-1, TNF-, and
hemokines,  in  order  to  amplify  the  inﬂammatory  response
nd  eliminate  the  agent  causing  the  aggression,21 thereby
laying  a  central  role  in  the  defense  against  pathogens  and
umor  cells.19 The  M1  phenotype  alters  the  permeability  of
he  BBB,  allowing  the  entry  of  immune  mediators,  natural
iller  cells  (NK)  and  lymphocytes.  This  immune  response
romotes  both  tissue  repair  and  neuronal  damage.21 The
ttack  on  native  neuronal  cells  can  have  serious  conse-
uences  if  the  process  deregulates19 and  becomes  chronic,
here  the  M1  phenotype  becomes  phagocytic  and  harmful,
s  occurs  in  neurological  diseases,  including  AD.4 Addi-
ionally,  deregulated,  active  microglia  may  contribute  to
athological  neovascularization  in  the  brain  and  retina.
he  precise  mechanisms  of  this  process  are  not  yet  fully
nderstood.19
Reactive  astrogliosis  is  an  astrocyte  response  to  polyeti-
logical  insults  to  the  CNS,  characterized  by  a  jump  in
strocyte  numbers  (hyperplasia/proliferation),  increases  in
he  number  and  length  of  astroglial  processes,  larger
ell  body  size  (hypertrophy),  migration,  and  upregula-
ion  of  cytoskeletal  components  such  as  GFAP,  vimentin,
nd  nestin.25 Thus,  an  astrocyte  phenotype  change  results
n  the  expression  of  non-detectable  molecules  in  resting
stroglia,21 such  as  the  enzyme  heme  oxygenase  1  (HO-1),26
nd  a  reduction  in  the  synthesis  of  glutamine  synthetase
GS).  The  cerebral  astrocytes  of  AD  patients  have  demon-
trated  increased  GFAP  expression.26 Reactive  astrocytes
roduce  NO  as  an  autocrine  apoptosis  mediator21 and  can
ecrete  inﬂammatory  cytokines  such  as  IL-1,  IL-6,  IL-8,Please  cite  this  article  in  press  as:  Fernández-Albarral  JA,  et  a
J  Optom.  (2018),  https://doi.org/10.1016/j.optom.2018.07.00
nﬂammatory  chemokines,  and  other  chemokines  involved
n  recruiting  microglia,  monocytes/macrophages,  T  lympho-
ytes  and  dendritic  cells.25 Because  of  this,  astrocytes  are
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onsidered  immunocompetent  cells.  Astrogliosis  may  favor
ither  neuronal  survival  or  the  formation  of  a  glial  scar  that
revents  the  regenerative  process.21 Reactive  astroglia  have
een  associated  with  the  stimulation  of  higher  metabolic
ctivity,  upregulation  of  cytoprotective  factors  and  antiox-
dant  defenses  that  protect  neurons  from  free  radicals,
estoration  of  the  neurotransmitter  balance,  and  regulation
f  ion  and  water  concentrations.  When  the  CNS  is  injured,
eactive  astrocytes  migrate  to  the  damaged  site,  isolate  the
njured  area,  and  remove  pathogens,  dead  cells,  and  cellular
ebris,  and  then  remodel  the  nerve  tissue.  Chronic  astroglio-
is,  however,  is  typically  detrimental,  directly  or  indirectly
amaging  neurons  and  the  vasculature  while  also  inhibiting
issue  repair.  Through  the  production  of  vascular  endothe-
ial  growth  factor  (VEGF),  astrogliosis  exacerbates  disease
rogression  by  increasing  vascular  permeability,  affecting
he  properties  of  the  BBB,  facilitating  the  inﬁltration  of
eripheral  immune  cells,  and  even  by  facilitating  neovas-
ularization.  Astroglia  also  produce  molecules  that  inhibit
xonal  repair  and  regeneration,  triggering  neurotoxicity  and
econdary  damage  in  nearby  neurons  and  glial  cells.  When
ysfunctional,  astroglia  can  also  constitute  the  primary
athogenic  element.25
Neuroinﬂammation  essentially  depends  on  the  activa-
ion  of  microglia  and  astrocytes,  which  respond  to  various
njuries  and  stimulations  through  the  expression  and  release
f  molecules  that  subsequently  cause  oxidative  stress.  Cyto-
oxic  activation  and  inﬂammatory  factors  stimulate  glial
ells  to  release  proinﬂammatory  signals,  creating  a  vicious
ycle  of  neuroinﬂammation  and  oxidative  stress,  resul-
ing  in  an  autoinﬂammatory  condition.  In  this  situation,
roinﬂammatory  cytokines  secreted  by  active  microglia
nhibit  astrocytic  gap  junction  communication,  and  the
strocytic  neuronal  support  function  is  affected.  This  has
een  observed  in  AD  and  could  explain  the  cell  death,
lthough  it  may  also  play  a  defensive  role,  preventing  the
iffusion  of  toxic  molecules.  The  microglia  also  release
he  neurotransmitter  glutamate,  which  triggers  excito-
oxic  neurodegeneration  and  cell  death  in  astrocytes  and
ligodendrocytes.4 Astrocytic  glutamate  uptake  leads  to
euronal  loss.  Elevated  levels  of  TNF- have  been  shown
o  stimulate  BDNF  secretion,  supporting  neuronal  survival.25
athogens  themselves  are  able  to  recruit  proinﬂammatory
icroglia  and  perpetuate  the  pathology.19 The  accumula-
ion  of  active  microglia  and  reactive  astrocytes  is  a  common
eature  in  neurodegenerative  diseases,  including  AD.21
eurodegeneration, glial response and
lzheimer’s
t  has  been  shown  that  both  microglia  and  astrocytes,  not
eurons,  are  the  main  source  of  N-terminally  truncated
  peptides  that  can  be  found  in  amyloid  deposits.2 A
laques  stimulate  the  factors  and  proteins  that  induce
he  production  of  inﬂammatory  cytokines  and  chemokines.
eregulated  proinﬂammatory  cytokines  and  chemokines
ave  been  found  in  AD.  Certain  forms  of  inﬂammation  andl.  Retinal  glial  changes  in  Alzheimer’s  disease  --  A  review.
1
D.4 It  is  not  known  whether  glial  activation  is  the  cause
r  a  consequence  of  AD,  but  it  certainly  contributes  to  its
evelopment.
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Table  1  Retinal  changes  in  Alzheimer’s  disease.
Reduction  in  the  number  of
retinal  ganglion  cells  (RGC)
6,28,32,41--43
Decreased  thickness  in  the
retinal  nerve  ﬁber  layer
(RNFL)
6,28,31,34--36,38,42--44
Decreased  choroidal  thickness
in  the  foveal  area
6,30,45--47
Vascular  disorders 39,48--50
6,40,51,52
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A  oligomers  induce  a  potent  inﬂammatory  response  and
distort  the  phagocytic  microglial  response,  leading  to  the
excessive  and  sustained  production  of  inﬂammatory  medi-
ators  that  could  explain  neurotoxicity  and  neuronal  loss.
Astrogliosis  is  also  involved  in  the  neural  degeneration  asso-
ciated  with  AD.2 Dysfunction  in  the  astrocytic  regulation  of
microglial  phagocytosis  has  been  observed  in  AD.4
One  way  in  which  A  accumulation  may  lead  to  neurode-
generation  is  through  oxidative  stress  whereby  molecules,
such  as  deoxyribonucleic  acid  (DNA)  and  proteins,  are  dam-
aged  due  to  excessive  oxidation  resulting  from  an  imbalance
between  oxidant  and  antioxidant  activity.  This  imbalance
may  be  due  to  the  oxidizing  properties  of  the  A  peptide,
which  is  thought  to  produce  hydrogen  peroxide  and  induces
ROS  accumulation.  It  appears  that  astrocytes  are  able  to
release  NO,  which  is  an  ROS,  in  an  attempt  to  counteract  the
reduced  cerebral  blood  ﬂow  in  AD.  Such  a  release  could  be
counterproductive  if  NO  levels  become  toxic.  In  degenera-
tive  disorders,  oxidative  stress  initiates  apoptosis  in  healthy
cells.  In  response  to  this  apoptosis,  the  complement  system
can  be  activated  to  remove  debris  derived  from  cell  death
which,  under  normal  circumstances,  is  deactivated  upon
completion  of  the  process.  However,  it  has  been  observed
that  in  AD,  this  deactivation  process  can  be  abandoned  when
the  complement  system  response  is  exacerbated,  which  also
leads  to  cell  death.  When  microglia  detect  that  the  com-
plement  system  has  been  activated,  they  become  active  as
well,  and  have  been  associated  with  the  pathogenesis  of  AD,
age-related  macular  degeneration  (AMD),  and  glaucoma.27
In  vivo  and  in  vitro  studies  suggest  that  microglia  recruited
to  A  plaques  sites  are  able  to  surround  and  phagocytize
A  peptides.  The  A  deposits  are  responsible  for  microglial
activation  in  a  way  that  is  strictly  dependent  on  the  amyloid
load.4 In  turn,  microglia  can  produce  complementary  factors
and  thus  reinforce  the  activation  of  the  complement  system
response  by  creating  a  vicious  cycle.27
Microglial  activation  and  the  production  of  proinﬂam-
matory  mediators  by  neurons  positive  for  phosphorylated
tau  can  contribute  to  neuronal  death  and  disease  progres-
sion  in  neurodegenerative  tauopathies  such  as  AD.  Although
plaques  and  tangles  remain  the  major  hallmarks  of  AD,  stud-
ies  show  that  activated  microglia  are  one  of  the  major
players  in  neuroinﬂammation,  along  with  plaque  deposition
and  astrocyte  stimulation.4
AD and  the eye
The  increasing  prevalence  of  AD,  combined  with  the  need  to
treat  the  disease  in  its  early  stages  before  irreversible  neu-
rological  damage  occurs,  prompts  us  to  search  for  accessible
in  vivo  brain  structures  that  allow  for  early  diagnosis  of  the
disease.8
The  retina  and  optic  nerve  share  an  embryologic  origin
with  the  brain,  and  have  similar  patterns  of  vascularization,
self-regulating  blood  ﬂow,  and  blood--tissue  barrier  func-
tions.  As  part  of  the  CNS,  the  retina  has  a  speciﬁc  immune
privilege  provided  by  the  BBB.  The  blood--retinal  barrierPlease  cite  this  article  in  press  as:  Fernández-Albarral  JA,  et  a
J  Optom.  (2018),  https://doi.org/10.1016/j.optom.2018.07.00
(BRB)  is  similar  in  structure  to  the  components  and  mecha-
nisms  of  the  BBB.2
Because  of  these  similarities,  the  retina  can  be  inspected
to  detect  AD  markers  such  as  A  deposition.  The  retina  has
t
s
dVisual  ﬁeld  reduction  (VF)
Accumulation  of  tau  and  A 29,37,53,54
een  shown  to  be  an  important  tool  for  the  in  vivo  visualiza-
ion  of  changes  in  AD,  their  pathogenesis,  and  progression
nd  response  to  AD  therapies  (Table  1).
Post-mortem  analyses  of  the  retinas  of  AD  patients  have
evealed  signiﬁcant  axonal  degeneration  in  the  optic  nerve
ead  and  a  reduced  number  of  retinal  ganglion  cells  (RGCs)
ssociated  with  reduced  thickness  in  the  retinal  nerve  ﬁber
ayer  (RNFL).28
Using  immunohistochemical  techniques,  the  presence  of
oth  tau  and  A  has  been  demonstrated  in  the  human
etina.  Accumulation  of  APP  has  been  shown  in  RGCs  and
he  RNFL.  Retinal  deposits  of  phosphorylated  tau  have  also
een  reported  in  the  retinas  of  AD  patients.29
The  use  of  several  different  non-invasive  techniques
akes  it  possible  to  analyze  in  vivo  the  retinal  changes  that
ccur  with  AD.
OCT  allows  us  to  determine  RNFL  thickness  and  RGC  loss.
atients  with  AD  present  peripapillary  decreases  in  RNFL
hickness,  with  the  most  pronounced  changes  occurring  in
he  superior  quadrant  of  the  retina,31 as  well  as  a  decreased
umber  of  RGCs  in  the  temporal  foveal  region,32 which
s  most  pronounced  in  the  foveal  and  parafoveal  region.33
sing  OCT,  several  patterns  of  RNFL  thinning  are  evident
n  Alzheimer’s  patients,  including  retinal  nerve  ﬁber  loss  in
he  superior  retina,34 superior  and  nasal  retina,35 and  the
uperior  and  inferior  retina.36 It  has  been  postulated  that
NFL  deﬁciencies  may  be  the  earliest  sign  of  AD,  even  before
amage  to  the  hippocampus  region  occurs,  resulting  in  mem-
ry  changes.30 A  statistically  signiﬁcant  generalized  loss  of
oveal  choroid  thickness  in  patients  with  mild  and  moder-
te  AD  has  been  found  using  optical  coherence  tomography
OCT).30
Recent  studies  suggest  that  fundus  auto-ﬂuorescence
FAF),  a  method  for  detecting  highly  ﬂuorescent  structures,
ay  be  used  in  conjunction  with  OCT  to  analyze  structures
f  interest,  leading  to  a  possible  visualization  of  perimacular
nd  perivascular  A  deposits,  primarily  in  the  outer  plexi-
orm  layer,  the  ganglion  cell  layer  (GCL)  and  the  RNFL  of  AD
atients.37
Confocal  scanning  laser  ophthalmoscopy  has  revealed
hanges  at  the  optic  nerve  head  in  AD  patients  in  compar-
son  to  age-matched  controls,  demonstrating  a  signiﬁcant
ecrease  in  RNFL  thickness  in  AD  patients  compared  with
ontrols,  as  well  as  larger  cup-to-disc  ratios.38l.  Retinal  glial  changes  in  Alzheimer’s  disease  --  A  review.
1
Using  retinography,  vascular  alterations  have  been  iden-
iﬁed  in  patients  with  AD.  The  retinal  vessels  of  AD  patients
how  vascular  attenuation,  arterial  and  venous  caliber
ecreases,  and  decreased  venous  ﬂow.39
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The  visual  ﬁeld  (VF)  reduction  shown  in  AD  patients,
ccurring  predominantly  in  the  lower  ﬁeld,  is  directly
elated  to  RNFL  thinning  found  in  the  superior  quadrant.40
lia and the eye
he  retina,  although  developmentally  part  of  the  brain,
s  a  unique  CNS  structure  in  many  aspects.  The  glial  cells
f  the  retina  are  one  example  of  this.  In  the  retina,  the
rincipal  glial  cells  are  the  Müller  cells,17 which  together
ith  the  astrocytes  constitute  the  macroglia  of  the  human
etina.  In  addition  to  macroglial  cells,  the  retina  contains
icroglial  cells,  the  resident  immune  cells  of  the  retina.55
he  microglia  are  blood-derived  phagocytic  cells.56
The  retinal  microglia  are  mainly  located  in  the  plexi-
orm  layers,  the  GCL,  and  the  RNFL,  and  possess  highly
obile  extensions  that  interact  with  the  surrounding  envi-
onment.57 Microglial  cells  are  essential  for  normal  retinal
rowth,  neurogenesis,58 and  proper  formation  of  retinal
lood  vessels.59 They  interact  with  Müller  cells  to  form  a
etwork  that  serves  as  a  control  system  for  trophic  factor  in
etinal  degeneration.2
Microglial  communication  with  neurons,  the  vascular  sys-
em,  and  the  macroglia  is  mediated  by  a  diverse  range  of
actors.  These  include  chemokines,  cytokines,  nucleotides,
urface  proteins  and  adhesion  molecules.  The  microglia  may
e  activated  by  a  perturbation  of  chemokines  and/or  recep-
or  expression.56 Activated  microglia  can  proliferate  and
igrate  to  regions  of  retinal  damage,  where  their  mor-
hological  changes  are  often  accompanied  by  changes  in
ignaling  and  gene  expression.60 They  are  involved  in  phago-
ytosis,  secretion  of  trophic  factors,  and  active  remodeling
f  neurons  and  synapses.56
Retinal  microglial  cells  perform  various  tasks  that  are
ssential  for  the  normal  physiological  development  of  the
etina,  and  are  constantly  in  a  close  relationship  with  neu-
ons.25 The  morphology  of  astrocytes  in  the  human  retina
hanges  from  the  star  shape  in  the  GCL  to  the  elongated
hape  in  the  RNFL.  The  somas  of  human  astrocytes  can
ainly  be  found  in  the  layers  mentioned  above,  but  exten-
ions  of  these  can  be  found  even  in  the  inner  nuclear  layer.61
ouse  astrocytes,  however,  are  star-shaped  and  can  only  be
ound  in  the  GCL  and  in  the  RNFL.62
Müller  cells  are  an  anatomical  link  between  the  retinal
eurons  and  structures  such  as  the  retinal  blood  vessels,
he  vitreous  body,  and  the  subretinal  space,  which  need  to
xchange  various  molecules.63 Astrocytes  and  Müller  cells
aintain  the  ion  and  water  homeostasis  of  the  retinal  tissue,
ncluding  the  pH,64 as  well  as  the  homeostasis  of  neurotrans-
itters  such  as  glutamate  and  gamma-aminobutyric  acid
GABA).65
Macroglial  cells  are  also  involved  in  retinal  glucose
etabolism,  providing  retinal  neurons  with  the  neces-
ary  nutrients  for  oxidative  metabolism,  and  in  removing
etabolic  waste  products.  Müller  cells  and  astrocytes  havePlease  cite  this  article  in  press  as:  Fernández-Albarral  JA,  et  a
J  Optom.  (2018),  https://doi.org/10.1016/j.optom.2018.07.00
lso  been  demonstrated  to  be  more  resistant  to  oxida-
ive  damage  than  neurons,  due  to  their  high  concentrations
f  antioxidants  that  protect  them  against  such  damage.25
hese  antioxidants,  such  as  glutathione,  which  are  provided
p
t
c
m PRESS
J.A.  Fernández-Albarral  et  al.
o  the  neurons,  eliminate  free  radicals  and  reactive  oxy-
en  compounds.63 Another  neuroprotective  mechanism  is
he  uptake  and/or  detoxiﬁcation  of  potentially  harmful  sub-
tances,  which  involves  the  phagocytosis  of  debris  from  dead
eurons  or  retinal  pigment  epithelial  cells.66 Astrocytes  and
üller  cells  are  involved  in  regulating  local  blood  ﬂow  in
esponse  to  changes  in  neuronal  activity.  Substances  such  as
rostaglandins  (PG),  NO,  and  arachidonic  acid  (AA),  which
egulate  blood  ﬂow  in  the  CNS,  are  produced  by  astrocytes.67
acroglial  cells  exercise  their  barrier  properties  in  the  reti-
al  capillaries,  called  the  BRB.25
As  mentioned  above,  astroglial  cells  defend  the  CNS,
nd  therefore  the  retina,  from  damage  through  a  process
alled  reactive  gliosis.  This  gliosis  is  triggered  in  response  to
rauma,  ischemic  damage,  neurodegeneration,  or  neuroin-
ammation.68 Müller  cells,  due  to  their  radial  distribution,
re  usually  one  of  the  ﬁrst  types  of  glial  cells  to  detect
etinal  damage,  providing  rapid  response  to  any  change  in
he  retinal  microenvironment.69 Müller  cell  gliosis  is  cha-
acterized  by  both  non-speciﬁc  and  therapeutic  responses,
pregulation  of  GFAP,  and  the  activation  of  extracellular
ignal-regulated  kinases  (ERK).63 GFAP  upregulation  is  there-
ore  used  as  a  common  marker  for  reactive  Müller  cells  and
s  an  indicator  of  retinal  stress,  retinal  injury,  and  Müller
ell  activation.  Practically  all  retinal  diseases  are  associated
ith  Müller  cell  gliosis.70
After  retinal  detachment,  Müller  cells  migrate  to  the
ffected  area  and  react  by  establishing  a  glial  scar,  replac-
ng  degenerated  neurons  and  photoreceptors.71 Glial  scars
nvolve  the  expression  of  inhibitory  molecules  on  the  surface
f  reactive  glial  cells,  which  inhibit  both  regular  tissue  repair
nd  neurodegeneration,  harming  the  function  and  structure
f  retinal  neurons.69
Müller  cell  gliosis  has  both  cytoprotective  and  cytotoxic
ffects  on  retinal  neurons.72 In  the  context  of  a  threat  to  the
etina,  the  so-called  conservative  or  non-proliferative  glio-
is  is  neuroprotective,  releasing  neurotrophic  factors  and
ntioxidants  which  favor  neuronal  survival  and  limit  the
xtent  of  the  tissue  damage.73 The  most  severe  injuries  pro-
oke  another  response  described  as  massive  or  proliferative,
n  which  gliosis  becomes  detrimental  to  the  retinal  tissue
nd  increases  neuronal  death.63
A  possible  trigger  for  the  transition  from  conservative
o  massive  gliosis  is  a  breakdown  of  the  BRB,  augmenting
oth  the  retinal  and  vitreous  content  of  growth  factors,
ytokines  and  inﬂammatory  factors,  and  allowing  the  inﬁl-
ration  of  blood-derived  immune  cells.74 The  excessive  and
rolonged  expression  of  VEGF  after  massive  gliosis  can  lead
o  retinal  inﬂammation,  neovascularization  and  vascular
esions.75 High  concentrations  of  NO  after  Müller  cell  acti-
ation  can  damage  neurons,76 while  lower  levels  may  have
 protective  effect,  as  in  the  protection  of  neurons  against
lutamate  excitotoxicity  and  decreased  retinal  ischemia  via
ts  vasodilator  effect.77
Another  important  feature  of  gliotic  Müller  cells  is  their
otent  cross-communication  with  cells  from  the  immune  sys-
em.  Molecules  from  inﬂammatory  cells  may  activate  Müller
ells,  and  these  cells  may  express  a  wide  variety  of  inﬂam-l.  Retinal  glial  changes  in  Alzheimer’s  disease  --  A  review.
1
ation  related  factors,  such  as  TNF-.69
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Table  2  Glial  activation  in  Alzheimer’s  disease.
Human  retinas
Microglial  activation  increased  MHC-II 78
Macroglial  activation 41
Retinas  of  transgenic  mice
Microglial  activation  increased  F4/80 47,80,84
Morphological  changes 80,81
Increased  IBA-1 39,81,84
Macroglial  activation  increased  GFAP  and  S100 81,85,86
Morphological  changes  in  astrocytes 85,87,88
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Retinal glia in AD
Retinal  glial  cells  can  establish  signiﬁcant  communication
amongst  themselves,  which  have  been  suggested  to  act  as
mediators  of  neuronal-glial  interactions,  acting  as  sensors
for  neurotransmission  signals,  and  contributing  to  the  main-
tenance  of  neuronal  activity  and  homeostasis  in  the  healthy
CNS.2
The  glia,  as  a  population  of  immune  cells  residing  in  the
retina  and  optic  nerve,  are  able  to  activate  and  respond
rapidly  to  any  type  of  damage.25 Changes  in  glial  cells  have
been  found  in  the  retinas  of  AD  patients  (Table  2).  Upregula-
tion  of  MHC-II  expression  (a  microglial  reactivity  marker)  has
been  observed  in  the  donor  retinas  of  AD  patients  in  com-
parison  to  those  donated  by  normal  patients.  This  increase
occurs  in  the  absence  of  lymphocytic  inﬁltrate,  suggesting
that  the  pathogenesis  of  the  retina  in  AD  may  be  different
from  that  observed  in  certain  areas  of  the  brain.78
Blanks  et  al.79 observed  an  increase  in  the  proportion  of
astrocytes  and  their  immunoreactivity,  especially  in  RGCs,
as  well  as  in  the  radial  processes  of  Müller  cells  in  the  retinas
of  AD  patients.
Different  models  of  transgenic  mice  have  been  used  to
study  the  retinal  glia  in  AD.  Ning  et  al.47 used  two  strains
of  mouse  models  of  AD  with  gene  mutations  for  PSEN-1  and
APP  to  study  the  immunoreactivity  of  F4/80  glycoprotein
(mouse  retinal  microglial  marker),  monocyte  chemotactic
protein  1  (MCP-1),  APP  and  A,  as  well  as  to  perform  a  TUNEL
test  (Terminal  deoxy-nucleotidyl-Uridin-triphosphate,  dUPT,
Nick-End  Labeling  assay)  which  determines  cell  death  by
apoptosis.  Sample  comparisons  were  made  between  differ-
ent  age  groups  (7.8,  10.5,  and  27  months)  and  between
transgenic  mice  and  the  wild-type  control  group  (WT).  The
results  showed  that  there  was  an  age-associated  increase  in
the  inﬂammatory  cytokine  MCP-1  and  the  microglial  marker
F4/80  in  the  APPswe/PSM146L  transgenic  mice.  This  sug-
gests  that  RGCs  increase  the  production  of  MCP-1  in  response
to  A,  and  that  the  microglia  proliferate  to  the  stimulation
of  MCP-1.  This  occurs  in  parallel  with  the  increased  apoptosis
in  the  GCL.
In  a  study  by  Pérez  et  al.80,  the  retinas  of
APPswe/PS1E9  transgenic  mice  and  non-transgenic
mice  between  12  and  19  months  of  age  were  compared,Please  cite  this  article  in  press  as:  Fernández-Albarral  JA,  et  a
J  Optom.  (2018),  https://doi.org/10.1016/j.optom.2018.07.00
ﬁnding  greater  microglial  activation  in  the  mutant  mice
than  in  the  control  group  at  all  ages  evaluated.  This  was
evidenced  by  an  increase  in  F4/80  immunoreactivity  as  well
as  in  morphological  changes,  including  increased  thickness
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n  the  microglial  processes,  which  made  them  appear  more
endritic  in  the  transgenic  group  than  in  the  control.  How-
ver,  no  changes  were  observed  in  cell  body  size.  The  same
tudy  evaluated  patterns  of  GFAP  immunoreactivity,  reveal-
ng  similar  patterns  in  both  mutated  and  non-transgenic
ice  regardless  of  age  and  sex.  This  immunoreactivity
as  restricted  to  the  distal  portion  of  Müller  cells  and
strocytes.
The  retinas  of  Tg2576  transgenic  mice  studied  by  Liu
t  al.81 showed  A  plaques  with  increased  microvascular
eposition  of  A  and  inﬂammation.  Immunization  with  A
nd  amylin  hormone,  or  islet  amyloid  polypeptide  (IAPP)
educed  retinal  A  deposits,  but  increased  microvascular
eposition  of  retinal  A  and  increased  neuroinﬂammation.
he  neuroinﬂammation  was  observed  to  be  partly  due  to
icroglial  inﬁltration,  as  evidenced  by  increased  immunore-
ctivity  in  microglial  marker  IBA-1  (ionized  calcium  binding
daptor  molecule  1),  which  in  some  cases  was  associated
ith  a  loss  of  retinal  architecture  from  the  GCL  to  the  outer
uclear  layer,  and  partly  due  to  astrogliosis  (labeled  with
nti-GFAP),  which  was  observed  in  transgenic  mice  not  only
n  the  NFL  and  in  the  GCL,  as  in  the  control  group,  but
lso  in  the  astrocyte  extensions  that  penetrated  the  GCL
o  reach  deeper  layers.  Müller  cell  process  staining  was
lso  increased.  These  observations  support  the  idea  that  A
mmunotherapy  increases  the  neuroinﬂammatory  response
n  the  retina.  Microglial  activation  and  astrogliosis  may  play
n  important  role  in  the  clearance  of  A  from  the  CNS.81
Macroglial  cells  have  been  found  to  be  polarized,  mean-
ng  that  their  membranes  have  different  domains  with
ifferentiated  molecular  functions  and  organization.  Some
tudies  indicate  that  this  polarization  is  lost  in  some  dis-
ases,  including  AD,  and  that  this  loss  is  characterized  by  a
ack  of  some  molecules  in  certain  membrane  domains  nor-
ally  rich  in  these,  which  entails  a  loss  of  normal  function.
he  membrane  domain  of  the  perivascular  endfeet  of  astro-
ytes  and  Müller  cells  contains  a  large  amount  of  aquaporin-4
rotein  (AQP4)  and  other  integral  membrane  molecules  that
ifferentiate  it  from  the  presynaptic  membrane.  This  high
oncentration  of  AQP4  is  the  result  of  several  anchoring
echanisms,  including  interaction  with  DAPC,  a  dystrophin
ssociated  protein  complex  such  as  -syntrophin.  Enger
t  al.82 performed  a  mouse  study  to  analyze  the  effect
f  a  lack  of  dystrophin  and  -syntrophin  on  the  macroglia
olarization  in  three  brain  regions  and  in  Müller  cells  using
QP4  as  a  marker.  They  concluded  that  both  proteins  played
n  important  role  in  the  organization  of  the  plasma  mem-
rane  molecules  in  the  endfeet  of  these  macroglial  cells,  but
hat  they  were  not  solely  responsible  for  polarization.  Other
tudies  demonstrated  how  1-integrin  deletion  affects  the
olarized  expression  of  AQP4  and  dystrophin.  In  addition,
he  increase  of  utrophin  following  a  lack  of  dystrophin  sug-
ests  that  utrophin  may  also  play  a  role  in  structuring  the
embranes  of  the  terminal  feet.82
In  the  study  by  Edwards  et  al.26 with  3xTG-AD  mice  and
 control  group  found  signs  of  glial  activation  in  Müller
ells  and  astrocytes  in  the  retinas  of  the  transgenic  group.
üller  cells  activation  was  evidenced  via  antibodies  againstl.  Retinal  glial  changes  in  Alzheimer’s  disease  --  A  review.
1
FAP  and  S100  proteins.  These  proteins  are  not  normally
xpressed  by  Müller  cells,  however,  GFAP  is  expressed  when
hey  become  reactive.  Astrocyte  activation  was  evidenced
hrough  the  observation  of  a  large  number  of  these  cells
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emonstrating  a  reactive  hypertrophic  morphology  in  the
xTgAD  retinas  in  comparison  to  the  control  group.  It  should
e  noted  that  these  signs  of  retinal  glial  activation  preceded
he  signs  of  glial  activation  in  the  brain.  The  S100B  protein
ncreases  the  production  of  A,  which  may  potentially  con-
ribute  to  the  formation  of  plaques.  In  the  study  by  Edwards
t  al.  there  also  appeared  to  be  an  increase  in  the  secre-
ion  of  the  S100  protein  in  the  retinas  of  the  transgenic
ice,  although  it  remains  to  be  investigated  whether  this
rotein  is  secreted  by  the  astrocytes  and  Müller  cells,  and
hat  consequences  this  increase  has  in  the  retina.  A  study
f  changes  in  the  expression  of  the  GS  enzyme  in  the  reti-
as  of  these  mice  was  also  conducted,  ﬁnding  no  signiﬁcant
hanges.  This  was  contrary  to  expectations,  since  reduced
evels  of  protoplasmic  astrocyte  expression  of  this  enzyme
ad  been  observed  in  the  brain.  However,  it  was  noted  that
hanges  in  GS  expression  were  observed  mostly  in  astrocytes
ssociated  with  amyloid  plaques,  and  no  such  plaques  were
bserved  in  the  sections  of  the  retinas  of  the  3xTG-AD  mice
sed  for  this  study.
Studies  of  the  retina  using  this  3xTgAD  mouse  model  that
ocused  on  the  microglia  also  detected  microglial  activation,
ut  without  conclusive  results  with  respect  to  the  control
roup.26
A  study  of  19-month-old  TgF344-AD  transgenic  mice  by
sai  et  al.45 showed  glial  activity  through  GFAP  expression
evealed  by  Müller  cell  staining.  Although  the  control  group
lso  showed  this  type  of  activity,  it  was  much  less  signiﬁcant
han  in  the  transgenic  mice.45
There  is  still  a  long  road  ahead  in  investigating  retinal
lia  to  understand  glial  activation.  Attention  must  be  paid
o  the  size  and  number  of  processes  in  the  microglia,  their
rotein  markers  of  activation,  and  the  increased  number
f  these  cells  observed  in  retinal  diseases.26 The  loss  of
acroglial  polarization  has  become  a  feature  to  be  studied
n  AD  and  its  models.  Future  research  should  address  studies
ith  mouse  lines  lacking  utrophin  and  dystrophin  to  provide
n  additional  insight  into  the  polarization  mechanisms  of
acroglial  cells  like  Müller  cells.82 Bosco  et  al.83 observed
arly  and  progressive  microglial  activation  in  the  retinas  of
ouse  models  of  glaucoma.  Several  authors  describe  simi-
arities  between  the  retinal  manifestations  of  glaucoma  and
D,  so  it  is  fair  to  consider  that  the  techniques  used  in  the
tudy  of  glia  in  glaucoma  can  be  used  to  evaluate  these  cells
n  the  retina  with  AD.2
Given  the  functional  importance  of  mitochondria  in
icroglial  activation,  and  that  mitochondrial  alterations  are
ecognized  in  the  brain  in  AD,  but  have  not  yet  been  eval-
ated  in  the  retina  (speciﬁcally  in  the  retinal  microglia),
t  seems  to  be  a  good  hypothesis  that  the  early  stages
f  microglial  activation  can  be  detected  using  neuroimag-
ng  of  speciﬁc  mitochondrial  markers.8 Along  these  lines,
itochondrial  translocator  protein  (TSPO;  18  kDa),  which
s  expressed  by  reactive  glia  and  is  a  biomarker  of  gliosis,
eems  a  promising  candidate  as  a  molecular  marker  for  the
isualization  of  retinal  inﬂammatory  cells.2Please  cite  this  article  in  press  as:  Fernández-Albarral  JA,  et  a
J  Optom.  (2018),  https://doi.org/10.1016/j.optom.2018.07.00
onclusion
s  part  of  the  CNS,  and  because  of  its  similarities  to  brain
issue,  the  retina  can  be  analyzed  to  detect  markers  of  AD, PRESS
J.A.  Fernández-Albarral  et  al.
nd  is  therefore  an  important  tool  for  visualization  of  the
isease.  Analyses  of  the  retinal  tissue  of  AD  patients  in  com-
ination  with  analyses  of  populations  of  transgenic  mice
odels  reveal  the  changes  that  retinal  glial  cells  undergo
s  Alzheimer’s  disease  develops.  The  study  of  morpholog-
cal  changes,  numbers,  microglial  and  macroglial  protein
arkers,  microglial  mitochondrial  markers,  and  macroglial
olarization  status  are  new  opportunities  for  research  in  AD.
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